#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Engineered proteins with tailored properties evolved from natural precursors have been playing an increasingly important role in a spectrum of agricultural , industrial , and biomedical applications .
2-1	16-26	Engineered	substance[2]	new[2]	coref	7-18[0_2]
2-2	27-35	proteins	substance[2]	new[2]	_	_
2-3	36-40	with	substance[2]	new[2]	_	_
2-4	41-49	tailored	substance[2]|abstract[3]	new[2]|new[3]	coref	21-5[160_3]
2-5	50-60	properties	substance[2]|abstract[3]	new[2]|new[3]	_	_
2-6	61-68	evolved	_	_	_	_
2-7	69-73	from	_	_	_	_
2-8	74-81	natural	substance[4]	new[4]	_	_
2-9	82-92	precursors	substance[4]	new[4]	_	_
2-10	93-97	have	_	_	_	_
2-11	98-102	been	_	_	_	_
2-12	103-110	playing	_	_	_	_
2-13	111-113	an	abstract[5]	new[5]	coref	5-7[37_5]
2-14	114-126	increasingly	abstract[5]	new[5]	_	_
2-15	127-136	important	abstract[5]	new[5]	_	_
2-16	137-141	role	abstract[5]	new[5]	_	_
2-17	142-144	in	_	_	_	_
2-18	145-146	a	abstract[6]	new[6]	_	_
2-19	147-155	spectrum	abstract[6]	new[6]	_	_
2-20	156-158	of	abstract[6]	new[6]	_	_
2-21	159-171	agricultural	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-22	172-173	,	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-23	174-184	industrial	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-24	185-186	,	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-25	187-190	and	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-26	191-201	biomedical	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-27	202-214	applications	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-28	215-216	.	_	_	_	_

#Text=For example , protein engineering holds the potential of transforming the metabolic drug landscape through the development of smart , stimulus-responsive drug systems .
3-1	217-220	For	_	_	_	_
3-2	221-228	example	_	_	_	_
3-3	229-230	,	_	_	_	_
3-4	231-238	protein	substance|abstract[9]	new|new[9]	coref|coref	4-5|4-5[18_9]
3-5	239-250	engineering	abstract[9]	new[9]	_	_
3-6	251-256	holds	_	_	_	_
3-7	257-260	the	abstract[10]	new[10]	_	_
3-8	261-270	potential	abstract[10]	new[10]	_	_
3-9	271-273	of	_	_	_	_
3-10	274-286	transforming	_	_	_	_
3-11	287-290	the	abstract[12]	new[12]	_	_
3-12	291-300	metabolic	abstract[12]	new[12]	_	_
3-13	301-305	drug	substance|abstract[12]	new|new[12]	coref	3-22
3-14	306-315	landscape	abstract[12]	new[12]	_	_
3-15	316-323	through	_	_	_	_
3-16	324-327	the	event[13]	new[13]	_	_
3-17	328-339	development	event[13]	new[13]	_	_
3-18	340-342	of	event[13]	new[13]	_	_
3-19	343-348	smart	event[13]|abstract[15]	new[13]|new[15]	coref	12-11[92_15]
3-20	349-350	,	event[13]|abstract[15]	new[13]|new[15]	_	_
3-21	351-370	stimulus-responsive	event[13]|abstract[15]	new[13]|new[15]	_	_
3-22	371-375	drug	event[13]|substance|abstract[15]	new[13]|giv|new[15]	_	_
3-23	376-383	systems	event[13]|abstract[15]	new[13]|new[15]	_	_
3-24	384-385	.	_	_	_	_

#Text=In industrial processes , protein engineering enables the production of enzymes that offer unique advantages compared with chemical catalysts , such as biodegradability , stereoselectivity , substrate specificity , functionality under relatively mild solvents , temperatures , pHs and pressures , and stability at extreme conditions .
4-1	386-388	In	_	_	_	_
4-2	389-399	industrial	abstract[16]	new[16]	_	_
4-3	400-409	processes	abstract[16]	new[16]	_	_
4-4	410-411	,	_	_	_	_
4-5	412-419	protein	substance|abstract[18]	giv|giv[18]	coref|coref	5-3|5-3[36_18]
4-6	420-431	engineering	abstract[18]	giv[18]	_	_
4-7	432-439	enables	_	_	_	_
4-8	440-443	the	event[19]	new[19]	_	_
4-9	444-454	production	event[19]	new[19]	_	_
4-10	455-457	of	event[19]	new[19]	_	_
4-11	458-465	enzymes	event[19]|substance	new[19]|new	coref	5-21[41_0]
4-12	466-470	that	_	_	_	_
4-13	471-476	offer	_	_	_	_
4-14	477-483	unique	abstract[21]	new[21]	_	_
4-15	484-494	advantages	abstract[21]	new[21]	_	_
4-16	495-503	compared	_	_	_	_
4-17	504-508	with	_	_	_	_
4-18	509-517	chemical	substance[22]	new[22]	_	_
4-19	518-527	catalysts	substance[22]	new[22]	_	_
4-20	528-529	,	substance[22]	new[22]	_	_
4-21	530-534	such	substance[22]	new[22]	_	_
4-22	535-537	as	substance[22]	new[22]	_	_
4-23	538-554	biodegradability	substance[22]|abstract	new[22]|new	_	_
4-24	555-556	,	substance[22]	new[22]	_	_
4-25	557-574	stereoselectivity	substance[22]|abstract	new[22]|new	_	_
4-26	575-576	,	substance[22]	new[22]	_	_
4-27	577-586	substrate	substance[22]|person|abstract[26]	new[22]|new|new[26]	_	_
4-28	587-598	specificity	substance[22]|abstract[26]	new[22]|new[26]	_	_
4-29	599-600	,	substance[22]	new[22]	_	_
4-30	601-614	functionality	substance[22]|abstract[27]	new[22]|new[27]	coref	19-24[146_27]
4-31	615-620	under	substance[22]|abstract[27]	new[22]|new[27]	_	_
4-32	621-631	relatively	substance[22]|abstract[27]|substance[28]	new[22]|new[27]|new[28]	_	_
4-33	632-636	mild	substance[22]|abstract[27]|substance[28]	new[22]|new[27]|new[28]	_	_
4-34	637-645	solvents	substance[22]|abstract[27]|substance[28]	new[22]|new[27]|new[28]	_	_
4-35	646-647	,	substance[22]|abstract[27]	new[22]|new[27]	_	_
4-36	648-660	temperatures	substance[22]|abstract[27]|substance	new[22]|new[27]|new	_	_
4-37	661-662	,	substance[22]|abstract[27]	new[22]|new[27]	_	_
4-38	663-666	pHs	substance[22]|abstract[27]|abstract	new[22]|new[27]|new	_	_
4-39	667-670	and	substance[22]|abstract[27]	new[22]|new[27]	_	_
4-40	671-680	pressures	substance[22]|abstract[27]|abstract	new[22]|new[27]|new	_	_
4-41	681-682	,	substance[22]	new[22]	_	_
4-42	683-686	and	substance[22]	new[22]	_	_
4-43	687-696	stability	substance[22]|abstract[32]	new[22]|new[32]	coref	21-12[0_32]
4-44	697-699	at	substance[22]|abstract[32]	new[22]|new[32]	_	_
4-45	700-707	extreme	substance[22]|abstract[32]|abstract[33]	new[22]|new[32]|new[33]	coref	19-20[0_33]
4-46	708-718	conditions	substance[22]|abstract[32]|abstract[33]	new[22]|new[32]|new[33]	_	_
4-47	719-720	.	_	_	_	_

#Text=Today , protein engineering also plays a critical role in advancing the emerging field of synthetic biology , including optimizing pathway enzymes and regulatory elements , balancing pathway redox equivalents , as well as tuning the expression of pathway genes .
5-1	721-726	Today	time	new	_	_
5-2	727-728	,	_	_	_	_
5-3	729-736	protein	substance|abstract[36]	giv|giv[36]	coref|coref	6-7|6-7[51_36]
5-4	737-748	engineering	abstract[36]	giv[36]	_	_
5-5	749-753	also	_	_	_	_
5-6	754-759	plays	_	_	_	_
5-7	760-761	a	abstract[37]	giv[37]	_	_
5-8	762-770	critical	abstract[37]	giv[37]	_	_
5-9	771-775	role	abstract[37]	giv[37]	_	_
5-10	776-778	in	_	_	_	_
5-11	779-788	advancing	_	_	_	_
5-12	789-792	the	abstract[38]	new[38]	_	_
5-13	793-801	emerging	abstract[38]	new[38]	_	_
5-14	802-807	field	abstract[38]	new[38]	_	_
5-15	808-810	of	abstract[38]	new[38]	_	_
5-16	811-820	synthetic	abstract[38]|abstract[39]	new[38]|new[39]	_	_
5-17	821-828	biology	abstract[38]|abstract[39]	new[38]|new[39]	_	_
5-18	829-830	,	_	_	_	_
5-19	831-840	including	_	_	_	_
5-20	841-851	optimizing	_	_	_	_
5-21	852-859	pathway	place|substance[41]	new|giv[41]	coref|coref	5-28|9-39[0_41]
5-22	860-867	enzymes	substance[41]	giv[41]	_	_
5-23	868-871	and	substance[41]	giv[41]	_	_
5-24	872-882	regulatory	substance[41]|abstract[42]	giv[41]|new[42]	coref	9-25[72_42]
5-25	883-891	elements	substance[41]|abstract[42]	giv[41]|new[42]	_	_
5-26	892-893	,	_	_	_	_
5-27	894-903	balancing	_	_	_	_
5-28	904-911	pathway	place|abstract[45]	giv|new[45]	coref	5-39
5-29	912-917	redox	object|abstract[45]	new|new[45]	_	_
5-30	918-929	equivalents	abstract[45]	new[45]	_	_
5-31	930-931	,	_	_	_	_
5-32	932-934	as	_	_	_	_
5-33	935-939	well	_	_	_	_
5-34	940-942	as	_	_	_	_
5-35	943-949	tuning	_	_	_	_
5-36	950-953	the	abstract[46]	new[46]	_	_
5-37	954-964	expression	abstract[46]	new[46]	_	_
5-38	965-967	of	abstract[46]	new[46]	_	_
5-39	968-975	pathway	abstract[46]|place|abstract[48]	new[46]|giv|new[48]	_	_
5-40	976-981	genes	abstract[46]|abstract[48]	new[46]|new[48]	_	_
5-41	982-983	.	_	_	_	_

#Text=There are two main strategies in protein engineering : rational design and directed evolution .
6-1	984-989	There	_	_	_	_
6-2	990-993	are	_	_	_	_
6-3	994-997	two	abstract[49]	new[49]	appos	6-10[52_49]
6-4	998-1002	main	abstract[49]	new[49]	_	_
6-5	1003-1013	strategies	abstract[49]	new[49]	_	_
6-6	1014-1016	in	abstract[49]	new[49]	_	_
6-7	1017-1024	protein	abstract[49]|substance|abstract[51]	new[49]|giv|giv[51]	coref	8-8[59_0]
6-8	1025-1036	engineering	abstract[49]|abstract[51]	new[49]|giv[51]	_	_
6-9	1037-1038	:	_	_	_	_
6-10	1039-1047	rational	abstract[52]	giv[52]	coref	7-1[53_52]
6-11	1048-1054	design	abstract[52]	giv[52]	_	_
6-12	1055-1058	and	abstract[52]	giv[52]	_	_
6-13	1059-1067	directed	abstract[52]	giv[52]	_	_
6-14	1068-1077	evolution	abstract[52]	giv[52]	_	_
6-15	1078-1079	.	_	_	_	_

#Text=Rational design , which is mostly carried out in silico , is knowledge-based , deterministic engineering of proteins .
7-1	1080-1088	Rational	abstract[53]	giv[53]	coref	7-13[55_53]
7-2	1089-1095	design	abstract[53]	giv[53]	_	_
7-3	1096-1097	,	_	_	_	_
7-4	1098-1103	which	_	_	_	_
7-5	1104-1106	is	_	_	_	_
7-6	1107-1113	mostly	_	_	_	_
7-7	1114-1121	carried	_	_	_	_
7-8	1122-1125	out	_	_	_	_
7-9	1126-1128	in	_	_	_	_
7-10	1129-1135	silico	substance	new	_	_
7-11	1136-1137	,	_	_	_	_
7-12	1138-1140	is	_	_	_	_
7-13	1141-1156	knowledge-based	abstract[55]	giv[55]	ana	8-3[0_55]
7-14	1157-1158	,	abstract[55]	giv[55]	_	_
7-15	1159-1172	deterministic	abstract[55]	giv[55]	_	_
7-16	1173-1184	engineering	abstract[55]	giv[55]	_	_
7-17	1185-1187	of	abstract[55]	giv[55]	_	_
7-18	1188-1196	proteins	abstract[55]|substance	giv[55]|giv	coref	15-20[122_0]
7-19	1197-1198	.	_	_	_	_

#Text=Thus , it needs prior information on the target protein such as a structural model , sequence relationship to homologs , and insights into its biophysical function .
8-1	1199-1203	Thus	_	_	_	_
8-2	1204-1205	,	_	_	_	_
8-3	1206-1208	it	abstract	giv	coref	9-13[69_0]
8-4	1209-1214	needs	_	_	_	_
8-5	1215-1220	prior	_	_	_	_
8-6	1221-1232	information	abstract[58]	new[58]	coref	28-55[243_58]
8-7	1233-1235	on	abstract[58]	new[58]	_	_
8-8	1236-1239	the	abstract[58]|substance[59]	new[58]|giv[59]	coref	9-10[0_59]
8-9	1240-1246	target	abstract[58]|substance[59]	new[58]|giv[59]	_	_
8-10	1247-1254	protein	abstract[58]|substance[59]	new[58]|giv[59]	_	_
8-11	1255-1259	such	abstract[58]|substance[59]	new[58]|giv[59]	_	_
8-12	1260-1262	as	abstract[58]|substance[59]	new[58]|giv[59]	_	_
8-13	1263-1264	a	abstract[58]|substance[59]|abstract[60]	new[58]|giv[59]|new[60]	_	_
8-14	1265-1275	structural	abstract[58]|substance[59]|abstract[60]	new[58]|giv[59]|new[60]	_	_
8-15	1276-1281	model	abstract[58]|substance[59]|abstract[60]	new[58]|giv[59]|new[60]	_	_
8-16	1282-1283	,	abstract[58]|substance[59]	new[58]|giv[59]	_	_
8-17	1284-1292	sequence	abstract[58]|substance[59]|abstract|abstract[62]	new[58]|giv[59]|new|new[62]	_	_
8-18	1293-1305	relationship	abstract[58]|substance[59]|abstract[62]	new[58]|giv[59]|new[62]	_	_
8-19	1306-1308	to	abstract[58]|substance[59]|abstract[62]	new[58]|giv[59]|new[62]	_	_
8-20	1309-1317	homologs	abstract[58]|substance[59]|abstract[62]|abstract	new[58]|giv[59]|new[62]|new	_	_
8-21	1318-1319	,	abstract[58]|substance[59]	new[58]|giv[59]	_	_
8-22	1320-1323	and	abstract[58]|substance[59]	new[58]|giv[59]	_	_
8-23	1324-1332	insights	abstract[58]|substance[59]|abstract[64]	new[58]|giv[59]|new[64]	_	_
8-24	1333-1337	into	abstract[58]|substance[59]|abstract[64]	new[58]|giv[59]|new[64]	_	_
8-25	1338-1341	its	abstract[58]|substance[59]|abstract[64]|abstract[65]	new[58]|giv[59]|new[64]|new[65]	_	_
8-26	1342-1353	biophysical	abstract[58]|substance[59]|abstract[64]|abstract[65]	new[58]|giv[59]|new[64]|new[65]	_	_
8-27	1354-1362	function	abstract[58]|substance[59]|abstract[64]|abstract[65]	new[58]|giv[59]|new[64]|new[65]	_	_
8-28	1363-1364	.	_	_	_	_

#Text=As a powerful approach to test general theories in protein chemistry , rational design can be achieved either by single-point mutation , exchange of elements of secondary structure , exchange of whole domains , or by fusion of enzymes .
9-1	1365-1367	As	_	_	_	_
9-2	1368-1369	a	_	_	_	_
9-3	1370-1378	powerful	_	_	_	_
9-4	1379-1387	approach	_	_	_	_
9-5	1388-1390	to	_	_	_	_
9-6	1391-1395	test	_	_	_	_
9-7	1396-1403	general	abstract[66]	new[66]	_	_
9-8	1404-1412	theories	abstract[66]	new[66]	_	_
9-9	1413-1415	in	abstract[66]	new[66]	_	_
9-10	1416-1423	protein	abstract[66]|substance|abstract[68]	new[66]|giv|new[68]	coref	12-32
9-11	1424-1433	chemistry	abstract[66]|abstract[68]	new[66]|new[68]	_	_
9-12	1434-1435	,	_	_	_	_
9-13	1436-1444	rational	abstract[69]	giv[69]	coref	11-11[86_69]
9-14	1445-1451	design	abstract[69]	giv[69]	_	_
9-15	1452-1455	can	_	_	_	_
9-16	1456-1458	be	_	_	_	_
9-17	1459-1467	achieved	_	_	_	_
9-18	1468-1474	either	abstract[70]	new[70]	coref	13-19[105_70]
9-19	1475-1477	by	abstract[70]	new[70]	_	_
9-20	1478-1490	single-point	abstract[70]	new[70]	_	_
9-21	1491-1499	mutation	abstract[70]	new[70]	_	_
9-22	1500-1501	,	_	_	_	_
9-23	1502-1510	exchange	abstract[71]	new[71]	_	_
9-24	1511-1513	of	abstract[71]	new[71]	_	_
9-25	1514-1522	elements	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
9-26	1523-1525	of	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
9-27	1526-1535	secondary	abstract[71]|abstract[72]|abstract[73]	new[71]|giv[72]|new[73]	coref	16-13[130_73]
9-28	1536-1545	structure	abstract[71]|abstract[72]|abstract[73]	new[71]|giv[72]|new[73]	_	_
9-29	1546-1547	,	_	_	_	_
9-30	1548-1556	exchange	event[74]	new[74]	_	_
9-31	1557-1559	of	event[74]	new[74]	_	_
9-32	1560-1565	whole	event[74]|abstract[75]	new[74]|new[75]	_	_
9-33	1566-1573	domains	event[74]|abstract[75]	new[74]|new[75]	_	_
9-34	1574-1575	,	_	_	_	_
9-35	1576-1578	or	_	_	_	_
9-36	1579-1581	by	_	_	_	_
9-37	1582-1588	fusion	event[76]	new[76]	_	_
9-38	1589-1591	of	event[76]	new[76]	_	_
9-39	1592-1599	enzymes	event[76]|substance	new[76]|giv	coref	24-12[184_0]
9-40	1600-1601	.	_	_	_	_

#Text=Novel computational tools have constantly improved , resulting in dramatic increase in the sizes of mutant libraries that can be designed .
10-1	1602-1607	Novel	_	_	_	_
10-2	1608-1621	computational	object[78]	new[78]	_	_
10-3	1622-1627	tools	object[78]	new[78]	_	_
10-4	1628-1632	have	_	_	_	_
10-5	1633-1643	constantly	_	_	_	_
10-6	1644-1652	improved	_	_	_	_
10-7	1653-1654	,	_	_	_	_
10-8	1655-1664	resulting	_	_	_	_
10-9	1665-1667	in	_	_	_	_
10-10	1668-1676	dramatic	abstract[79]	new[79]	_	_
10-11	1677-1685	increase	abstract[79]	new[79]	_	_
10-12	1686-1688	in	abstract[79]	new[79]	_	_
10-13	1689-1692	the	abstract[79]|quantity[80]	new[79]|new[80]	_	_
10-14	1693-1698	sizes	abstract[79]|quantity[80]	new[79]|new[80]	_	_
10-15	1699-1701	of	abstract[79]|quantity[80]	new[79]|new[80]	_	_
10-16	1702-1708	mutant	abstract[79]|quantity[80]|object[81]	new[79]|new[80]|new[81]	coref	19-11[143_81]
10-17	1709-1718	libraries	abstract[79]|quantity[80]|object[81]	new[79]|new[80]|new[81]	_	_
10-18	1719-1723	that	_	_	_	_
10-19	1724-1727	can	_	_	_	_
10-20	1728-1730	be	_	_	_	_
10-21	1731-1739	designed	_	_	_	_
10-22	1740-1741	.	_	_	_	_

#Text=Genome-scale metabolic models ( GEMs ) have informed and expanded variant design for many industrially relevant microorganisms .
11-1	1742-1754	Genome-scale	abstract[83]	new[83]	appos	11-5[0_83]
11-2	1755-1764	metabolic	person|abstract[83]	new|new[83]	_	_
11-3	1765-1771	models	abstract[83]	new[83]	_	_
11-4	1772-1773	(	_	_	_	_
11-5	1774-1778	GEMs	abstract	giv	_	_
11-6	1779-1780	)	_	_	_	_
11-7	1781-1785	have	_	_	_	_
11-8	1786-1794	informed	_	_	_	_
11-9	1795-1798	and	_	_	_	_
11-10	1799-1807	expanded	_	_	_	_
11-11	1808-1815	variant	object|abstract[86]	new|giv[86]	coref|coref	14-16[113_86]|25-27[201_0]
11-12	1816-1822	design	abstract[86]	giv[86]	_	_
11-13	1823-1826	for	abstract[86]	giv[86]	_	_
11-14	1827-1831	many	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
11-15	1832-1844	industrially	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
11-16	1845-1853	relevant	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
11-17	1854-1868	microorganisms	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
11-18	1869-1870	.	_	_	_	_

#Text=Furthermore , multiplex automated genome evolution ( MAGE ) and CRISPR/Cas systems have significantly improved the throughput of genome editing with precision and reduced cost and time required to explore many protein targets .
12-1	1871-1882	Furthermore	_	_	_	_
12-2	1883-1884	,	_	_	_	_
12-3	1885-1894	multiplex	abstract[89]	new[89]	appos	12-8[0_89]
12-4	1895-1904	automated	abstract[89]	new[89]	_	_
12-5	1905-1911	genome	abstract|abstract[89]	new|new[89]	coref	12-19
12-6	1912-1921	evolution	abstract[89]	new[89]	_	_
12-7	1922-1923	(	_	_	_	_
12-8	1924-1928	MAGE	abstract	giv	coref	13-4
12-9	1929-1930	)	_	_	_	_
12-10	1931-1934	and	_	_	_	_
12-11	1935-1945	CRISPR/Cas	organization|abstract[92]	new|giv[92]	coref	18-13[141_92]
12-12	1946-1953	systems	abstract[92]	giv[92]	_	_
12-13	1954-1958	have	_	_	_	_
12-14	1959-1972	significantly	_	_	_	_
12-15	1973-1981	improved	_	_	_	_
12-16	1982-1985	the	abstract[93]	new[93]	_	_
12-17	1986-1996	throughput	abstract[93]	new[93]	_	_
12-18	1997-1999	of	abstract[93]	new[93]	_	_
12-19	2000-2006	genome	abstract[93]|abstract	new[93]|giv	_	_
12-20	2007-2014	editing	_	_	_	_
12-21	2015-2019	with	_	_	_	_
12-22	2020-2029	precision	abstract	new	_	_
12-23	2030-2033	and	_	_	_	_
12-24	2034-2041	reduced	abstract[96]	new[96]	_	_
12-25	2042-2046	cost	abstract[96]	new[96]	_	_
12-26	2047-2050	and	_	_	_	_
12-27	2051-2055	time	time	new	_	_
12-28	2056-2064	required	_	_	_	_
12-29	2065-2067	to	_	_	_	_
12-30	2068-2075	explore	_	_	_	_
12-31	2076-2080	many	abstract[99]	new[99]	coref	13-23[108_99]
12-32	2081-2088	protein	substance|abstract[99]	giv|new[99]	coref	14-17
12-33	2089-2096	targets	abstract[99]	new[99]	_	_
12-34	2097-2098	.	_	_	_	_

#Text=For example , MAGE enables the rapid generation of billions of mutants by repeated insertion , deletion or mutation of DNA at multiple chromosomal targets .
13-1	2099-2102	For	_	_	_	_
13-2	2103-2110	example	_	_	_	_
13-3	2111-2112	,	_	_	_	_
13-4	2113-2117	MAGE	abstract	giv	coref	15-1[118_0]
13-5	2118-2125	enables	_	_	_	_
13-6	2126-2129	the	abstract[101]	new[101]	_	_
13-7	2130-2135	rapid	abstract[101]	new[101]	_	_
13-8	2136-2146	generation	abstract[101]	new[101]	_	_
13-9	2147-2149	of	abstract[101]	new[101]	_	_
13-10	2150-2158	billions	abstract[101]|quantity[102]	new[101]|new[102]	coref	19-15[0_102]
13-11	2159-2161	of	abstract[101]|quantity[102]	new[101]|new[102]	_	_
13-12	2162-2169	mutants	abstract[101]|quantity[102]	new[101]|new[102]	_	_
13-13	2170-2172	by	_	_	_	_
13-14	2173-2181	repeated	event[103]	new[103]	_	_
13-15	2182-2191	insertion	event[103]	new[103]	_	_
13-16	2192-2193	,	_	_	_	_
13-17	2194-2202	deletion	event	new	_	_
13-18	2203-2205	or	_	_	_	_
13-19	2206-2214	mutation	abstract[105]	giv[105]	_	_
13-20	2215-2217	of	abstract[105]	giv[105]	_	_
13-21	2218-2221	DNA	abstract[105]|substance[106]	giv[105]|new[106]	_	_
13-22	2222-2224	at	abstract[105]|substance[106]	giv[105]|new[106]	_	_
13-23	2225-2233	multiple	abstract[105]|substance[106]|abstract[108]	giv[105]|new[106]|giv[108]	_	_
13-24	2234-2245	chromosomal	abstract[105]|substance[106]|animal|abstract[108]	giv[105]|new[106]|new|giv[108]	_	_
13-25	2246-2253	targets	abstract[105]|substance[106]|abstract[108]	giv[105]|new[106]|giv[108]	_	_
13-26	2254-2255	.	_	_	_	_

#Text=Overall , the unprecedented capability of designing and building a large number of variants for rational protein design has placed increased demands on the throughput of screening and selection .
14-1	2256-2263	Overall	_	_	_	_
14-2	2264-2265	,	_	_	_	_
14-3	2266-2269	the	abstract[109]	new[109]	_	_
14-4	2270-2283	unprecedented	abstract[109]	new[109]	_	_
14-5	2284-2294	capability	abstract[109]	new[109]	_	_
14-6	2295-2297	of	_	_	_	_
14-7	2298-2307	designing	_	_	_	_
14-8	2308-2311	and	_	_	_	_
14-9	2312-2320	building	_	_	_	_
14-10	2321-2322	a	abstract[110]	new[110]	_	_
14-11	2323-2328	large	abstract[110]	new[110]	_	_
14-12	2329-2335	number	abstract[110]	new[110]	_	_
14-13	2336-2338	of	abstract[110]	new[110]	_	_
14-14	2339-2347	variants	abstract[110]|object[111]	new[110]|new[111]	coref	20-8[149_111]
14-15	2348-2351	for	abstract[110]|object[111]	new[110]|new[111]	_	_
14-16	2352-2360	rational	abstract[110]|object[111]|abstract[113]	new[110]|new[111]|giv[113]	coref	16-2[126_113]
14-17	2361-2368	protein	abstract[110]|object[111]|substance|abstract[113]	new[110]|new[111]|giv|giv[113]	coref	16-3
14-18	2369-2375	design	abstract[110]|object[111]|abstract[113]	new[110]|new[111]|giv[113]	_	_
14-19	2376-2379	has	_	_	_	_
14-20	2380-2386	placed	_	_	_	_
14-21	2387-2396	increased	abstract[114]	new[114]	_	_
14-22	2397-2404	demands	abstract[114]	new[114]	_	_
14-23	2405-2407	on	abstract[114]	new[114]	_	_
14-24	2408-2411	the	abstract[114]|abstract[115]	new[114]|new[115]	_	_
14-25	2412-2422	throughput	abstract[114]|abstract[115]	new[114]|new[115]	_	_
14-26	2423-2425	of	abstract[114]|abstract[115]	new[114]|new[115]	_	_
14-27	2426-2435	screening	abstract[114]|abstract[115]|abstract	new[114]|new[115]|new	coref	20-6[148_0]
14-28	2436-2439	and	abstract[114]|abstract[115]	new[114]|new[115]	_	_
14-29	2440-2449	selection	abstract[114]|abstract[115]|abstract	new[114]|new[115]|new	coref	15-13[120_0]
14-30	2450-2451	.	_	_	_	_

#Text=Directed evolution , on the other hand , mimics the process of natural selection through random mutagenesis to steer proteins or nucleic acids toward desired traits .
15-1	2452-2460	Directed	abstract[118]	giv[118]	coref	16-6[127_118]
15-2	2461-2470	evolution	abstract[118]	giv[118]	_	_
15-3	2471-2472	,	abstract[118]	giv[118]	_	_
15-4	2473-2475	on	abstract[118]	giv[118]	_	_
15-5	2476-2479	the	abstract[118]	giv[118]	_	_
15-6	2480-2485	other	abstract[118]	giv[118]	_	_
15-7	2486-2490	hand	abstract[118]	giv[118]	_	_
15-8	2491-2492	,	_	_	_	_
15-9	2493-2499	mimics	_	_	_	_
15-10	2500-2503	the	abstract[119]	new[119]	_	_
15-11	2504-2511	process	abstract[119]	new[119]	_	_
15-12	2512-2514	of	abstract[119]	new[119]	_	_
15-13	2515-2522	natural	abstract[119]|abstract[120]	new[119]|giv[120]	coref	24-9[183_120]
15-14	2523-2532	selection	abstract[119]|abstract[120]	new[119]|giv[120]	_	_
15-15	2533-2540	through	abstract[119]|abstract[120]	new[119]|giv[120]	_	_
15-16	2541-2547	random	abstract[119]|abstract[120]|event[121]	new[119]|giv[120]|new[121]	_	_
15-17	2548-2559	mutagenesis	abstract[119]|abstract[120]|event[121]	new[119]|giv[120]|new[121]	_	_
15-18	2560-2562	to	_	_	_	_
15-19	2563-2568	steer	_	_	_	_
15-20	2569-2577	proteins	substance[122]	giv[122]	coref	21-1[0_122]
15-21	2578-2580	or	substance[122]	giv[122]	_	_
15-22	2581-2588	nucleic	substance[122]|substance[123]	giv[122]|new[123]	_	_
15-23	2589-2594	acids	substance[122]|substance[123]	giv[122]|new[123]	_	_
15-24	2595-2601	toward	_	_	_	_
15-25	2602-2609	desired	abstract[124]	new[124]	coref	20-10[150_124]
15-26	2610-2616	traits	abstract[124]	new[124]	_	_
15-27	2617-2618	.	_	_	_	_

#Text=Unlike rational protein design , directed evolution requires neither prior knowledge of a protein ’s detailed structure nor prediction of the effects of various mutations .
16-1	2619-2625	Unlike	_	_	_	_
16-2	2626-2634	rational	abstract[126]	giv[126]	_	_
16-3	2635-2642	protein	substance|abstract[126]	giv|giv[126]	coref	16-14[129_0]
16-4	2643-2649	design	abstract[126]	giv[126]	_	_
16-5	2650-2651	,	_	_	_	_
16-6	2652-2660	directed	abstract[127]	giv[127]	coref	17-3[134_127]
16-7	2661-2670	evolution	abstract[127]	giv[127]	_	_
16-8	2671-2679	requires	_	_	_	_
16-9	2680-2687	neither	_	_	_	_
16-10	2688-2693	prior	_	_	_	_
16-11	2694-2703	knowledge	abstract[128]	new[128]	ana	17-6[0_128]
16-12	2704-2706	of	abstract[128]	new[128]	_	_
16-13	2707-2708	a	abstract[128]|abstract[130]	new[128]|giv[130]	_	_
16-14	2709-2716	protein	abstract[128]|substance[129]|abstract[130]	new[128]|giv[129]|giv[130]	coref	17-11[0_129]
16-15	2717-2719	’s	abstract[128]|substance[129]|abstract[130]	new[128]|giv[129]|giv[130]	_	_
16-16	2720-2728	detailed	abstract[128]|abstract[130]	new[128]|giv[130]	_	_
16-17	2729-2738	structure	abstract[128]|abstract[130]	new[128]|giv[130]	_	_
16-18	2739-2742	nor	abstract[128]	new[128]	_	_
16-19	2743-2753	prediction	abstract[128]|abstract[131]	new[128]|new[131]	_	_
16-20	2754-2756	of	abstract[128]|abstract[131]	new[128]|new[131]	_	_
16-21	2757-2760	the	abstract[128]|abstract[131]|abstract[132]	new[128]|new[131]|new[132]	_	_
16-22	2761-2768	effects	abstract[128]|abstract[131]|abstract[132]	new[128]|new[131]|new[132]	_	_
16-23	2769-2771	of	abstract[128]|abstract[131]|abstract[132]	new[128]|new[131]|new[132]	_	_
16-24	2772-2779	various	abstract[128]|abstract[131]|abstract[132]|abstract[133]	new[128]|new[131]|new[132]|new[133]	_	_
16-25	2780-2789	mutations	abstract[128]|abstract[131]|abstract[132]|abstract[133]	new[128]|new[131]|new[132]|new[133]	_	_
16-26	2790-2791	.	_	_	_	_

#Text=Indeed , directed evolution makes it possible to identify undiscovered protein sequences which have novel functions .
17-1	2792-2798	Indeed	_	_	_	_
17-2	2799-2800	,	_	_	_	_
17-3	2801-2809	directed	abstract[134]	giv[134]	coref	18-9[140_134]
17-4	2810-2819	evolution	abstract[134]	giv[134]	_	_
17-5	2820-2825	makes	_	_	_	_
17-6	2826-2828	it	abstract	giv	_	_
17-7	2829-2837	possible	_	_	_	_
17-8	2838-2840	to	_	_	_	_
17-9	2841-2849	identify	_	_	_	_
17-10	2850-2862	undiscovered	abstract[137]	new[137]	_	_
17-11	2863-2870	protein	substance|abstract[137]	giv|new[137]	coref	22-15
17-12	2871-2880	sequences	abstract[137]	new[137]	_	_
17-13	2881-2886	which	_	_	_	_
17-14	2887-2891	have	_	_	_	_
17-15	2892-2897	novel	abstract[138]	new[138]	_	_
17-16	2898-2907	functions	abstract[138]	new[138]	_	_
17-17	2908-2909	.	_	_	_	_

#Text=Moreover , synthetic biologists also increasingly rely on directed evolution to optimize engineered biological systems .
18-1	2910-2918	Moreover	_	_	_	_
18-2	2919-2920	,	_	_	_	_
18-3	2921-2930	synthetic	person[139]	new[139]	_	_
18-4	2931-2941	biologists	person[139]	new[139]	_	_
18-5	2942-2946	also	_	_	_	_
18-6	2947-2959	increasingly	_	_	_	_
18-7	2960-2964	rely	_	_	_	_
18-8	2965-2967	on	_	_	_	_
18-9	2968-2976	directed	abstract[140]	giv[140]	coref	19-4[142_140]
18-10	2977-2986	evolution	abstract[140]	giv[140]	_	_
18-11	2987-2989	to	_	_	_	_
18-12	2990-2998	optimize	_	_	_	_
18-13	2999-3009	engineered	abstract[141]	giv[141]	_	_
18-14	3010-3020	biological	abstract[141]	giv[141]	_	_
18-15	3021-3028	systems	abstract[141]	giv[141]	_	_
18-16	3029-3030	.	_	_	_	_

#Text=However , for directed evolution to be truly effective , very large libraries of mutants must be screened under conditions that closely match the desired functionality .
19-1	3031-3038	However	_	_	_	_
19-2	3039-3040	,	_	_	_	_
19-3	3041-3044	for	_	_	_	_
19-4	3045-3053	directed	abstract[142]	giv[142]	coref	20-20[153_142]
19-5	3054-3063	evolution	abstract[142]	giv[142]	_	_
19-6	3064-3066	to	abstract[142]	giv[142]	_	_
19-7	3067-3069	be	abstract[142]	giv[142]	_	_
19-8	3070-3075	truly	abstract[142]	giv[142]	_	_
19-9	3076-3085	effective	abstract[142]	giv[142]	_	_
19-10	3086-3087	,	_	_	_	_
19-11	3088-3092	very	object[143]	giv[143]	_	_
19-12	3093-3098	large	object[143]	giv[143]	_	_
19-13	3099-3108	libraries	object[143]	giv[143]	_	_
19-14	3109-3111	of	object[143]	giv[143]	_	_
19-15	3112-3119	mutants	object[143]|quantity	giv[143]|giv	coref	20-27[155_0]
19-16	3120-3124	must	_	_	_	_
19-17	3125-3127	be	_	_	_	_
19-18	3128-3136	screened	_	_	_	_
19-19	3137-3142	under	_	_	_	_
19-20	3143-3153	conditions	abstract	giv	_	_
19-21	3154-3158	that	_	_	_	_
19-22	3159-3166	closely	_	_	_	_
19-23	3167-3172	match	_	_	_	_
19-24	3173-3176	the	abstract[146]	giv[146]	_	_
19-25	3177-3184	desired	abstract[146]	giv[146]	_	_
19-26	3185-3198	functionality	abstract[146]	giv[146]	_	_
19-27	3199-3200	.	_	_	_	_

#Text=Thus , the throughput of screening for variants with improved traits is a major factor dictating the efficiency of directed evolution given that the libraries of random mutants can be easily on the scale of 108 – 109 .
20-1	3201-3205	Thus	_	_	_	_
20-2	3206-3207	,	_	_	_	_
20-3	3208-3211	the	abstract[147]	new[147]	coref	20-13[151_147]
20-4	3212-3222	throughput	abstract[147]	new[147]	_	_
20-5	3223-3225	of	abstract[147]	new[147]	_	_
20-6	3226-3235	screening	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
20-7	3236-3239	for	abstract[147]|abstract[148]	new[147]|giv[148]	_	_
20-8	3240-3248	variants	abstract[147]|abstract[148]|object[149]	new[147]|giv[148]|giv[149]	coref	24-23[0_149]
20-9	3249-3253	with	abstract[147]|abstract[148]|object[149]	new[147]|giv[148]|giv[149]	_	_
20-10	3254-3262	improved	abstract[147]|abstract[148]|object[149]|abstract[150]	new[147]|giv[148]|giv[149]|giv[150]	_	_
20-11	3263-3269	traits	abstract[147]|abstract[148]|object[149]|abstract[150]	new[147]|giv[148]|giv[149]|giv[150]	_	_
20-12	3270-3272	is	_	_	_	_
20-13	3273-3274	a	abstract[151]	giv[151]	_	_
20-14	3275-3280	major	abstract[151]	giv[151]	_	_
20-15	3281-3287	factor	abstract[151]	giv[151]	_	_
20-16	3288-3297	dictating	_	_	_	_
20-17	3298-3301	the	abstract[152]	new[152]	coref	25-32[202_152]
20-18	3302-3312	efficiency	abstract[152]	new[152]	_	_
20-19	3313-3315	of	abstract[152]	new[152]	_	_
20-20	3316-3324	directed	abstract[152]|abstract[153]	new[152]|giv[153]	coref	25-8[195_153]
20-21	3325-3334	evolution	abstract[152]|abstract[153]	new[152]|giv[153]	_	_
20-22	3335-3340	given	_	_	_	_
20-23	3341-3345	that	_	_	_	_
20-24	3346-3349	the	abstract[154]	new[154]	coref	22-14[170_154]
20-25	3350-3359	libraries	abstract[154]	new[154]	_	_
20-26	3360-3362	of	abstract[154]	new[154]	_	_
20-27	3363-3369	random	abstract[154]|quantity[155]	new[154]|giv[155]	coref	25-18[199_155]
20-28	3370-3377	mutants	abstract[154]|quantity[155]	new[154]|giv[155]	_	_
20-29	3378-3381	can	_	_	_	_
20-30	3382-3384	be	_	_	_	_
20-31	3385-3391	easily	abstract[156]	new[156]	_	_
20-32	3392-3394	on	abstract[156]	new[156]	_	_
20-33	3395-3398	the	abstract[156]	new[156]	_	_
20-34	3399-3404	scale	abstract[156]	new[156]	_	_
20-35	3405-3407	of	abstract[156]	new[156]	_	_
20-36	3408-3411	108	abstract[156]|quantity[157]	new[156]|new[157]	_	_
20-37	3412-3413	–	abstract[156]|quantity[157]	new[156]|new[157]	_	_
20-38	3414-3417	109	abstract[156]|quantity[157]|quantity	new[156]|new[157]|new	_	_
20-39	3418-3419	.	_	_	_	_

#Text=Proteins are engineered for properties such as affinity , selectivity , stability or enzymatic activity .
21-1	3420-3428	Proteins	object	giv	_	_
21-2	3429-3432	are	_	_	_	_
21-3	3433-3443	engineered	_	_	_	_
21-4	3444-3447	for	_	_	_	_
21-5	3448-3458	properties	abstract[160]	giv[160]	coref	27-3[218_160]
21-6	3459-3463	such	abstract[160]	giv[160]	_	_
21-7	3464-3466	as	abstract[160]	giv[160]	_	_
21-8	3467-3475	affinity	abstract[160]|abstract	giv[160]|new	_	_
21-9	3476-3477	,	abstract[160]	giv[160]	_	_
21-10	3478-3489	selectivity	abstract[160]|abstract	giv[160]|new	_	_
21-11	3490-3491	,	abstract[160]	giv[160]	_	_
21-12	3492-3501	stability	abstract[160]|abstract	giv[160]|giv	_	_
21-13	3502-3504	or	abstract[160]	giv[160]	_	_
21-14	3505-3514	enzymatic	abstract[160]|place|abstract[165]	giv[160]|new|new[165]	_	_
21-15	3515-3523	activity	abstract[160]|abstract[165]	giv[160]|new[165]	_	_
21-16	3524-3525	.	_	_	_	_

#Text=Often , when a cell based fluorescent readout is achievable , screening of engineered protein libraries is performed with fluorescence-activated cell sorting ( FACS ) to separate a population of cells into sub-populations based on fluorescent labeling .
22-1	3526-3531	Often	_	_	_	_
22-2	3532-3533	,	_	_	_	_
22-3	3534-3538	when	_	_	_	_
22-4	3539-3540	a	object[166]	new[166]	coref	22-21[0_166]
22-5	3541-3545	cell	object[166]	new[166]	_	_
22-6	3546-3551	based	_	_	_	_
22-7	3552-3563	fluorescent	abstract[167]	new[167]	_	_
22-8	3564-3571	readout	abstract[167]	new[167]	_	_
22-9	3572-3574	is	_	_	_	_
22-10	3575-3585	achievable	_	_	_	_
22-11	3586-3587	,	_	_	_	_
22-12	3588-3597	screening	abstract[168]	new[168]	coref	29-17[0_168]
22-13	3598-3600	of	abstract[168]	new[168]	_	_
22-14	3601-3611	engineered	abstract[168]|object[170]	new[168]|giv[170]	_	_
22-15	3612-3619	protein	abstract[168]|substance|object[170]	new[168]|giv|giv[170]	coref	27-30[223_0]
22-16	3620-3629	libraries	abstract[168]|object[170]	new[168]|giv[170]	_	_
22-17	3630-3632	is	_	_	_	_
22-18	3633-3642	performed	_	_	_	_
22-19	3643-3647	with	_	_	_	_
22-20	3648-3670	fluorescence-activated	abstract[172]	new[172]	appos	22-24[0_172]
22-21	3671-3675	cell	object|abstract[172]	giv|new[172]	coref	26-25[214_0]
22-22	3676-3683	sorting	abstract[172]	new[172]	_	_
22-23	3684-3685	(	_	_	_	_
22-24	3686-3690	FACS	abstract	giv	coref	24-36
22-25	3691-3692	)	_	_	_	_
22-26	3693-3695	to	_	_	_	_
22-27	3696-3704	separate	_	_	_	_
22-28	3705-3706	a	abstract[174]	new[174]	coref	26-28[216_174]
22-29	3707-3717	population	abstract[174]	new[174]	_	_
22-30	3718-3720	of	abstract[174]	new[174]	_	_
22-31	3721-3726	cells	abstract[174]|object	new[174]|new	coref	23-11[181_0]
22-32	3727-3731	into	_	_	_	_
22-33	3732-3747	sub-populations	abstract	new	ana	26-2
22-34	3748-3753	based	_	_	_	_
22-35	3754-3756	on	_	_	_	_
22-36	3757-3768	fluorescent	object[177]	new[177]	_	_
22-37	3769-3777	labeling	object[177]	new[177]	_	_
22-38	3778-3779	.	_	_	_	_

#Text=In this case , the phenotype-genotype connection is unbroken because the cells are selected directly .
23-1	3780-3782	In	_	_	_	_
23-2	3783-3787	this	event[178]	new[178]	_	_
23-3	3788-3792	case	event[178]	new[178]	_	_
23-4	3793-3794	,	_	_	_	_
23-5	3795-3798	the	abstract[180]	new[180]	_	_
23-6	3799-3817	phenotype-genotype	abstract|abstract[180]	new|new[180]	_	_
23-7	3818-3828	connection	abstract[180]	new[180]	_	_
23-8	3829-3831	is	_	_	_	_
23-9	3832-3840	unbroken	_	_	_	_
23-10	3841-3848	because	_	_	_	_
23-11	3849-3852	the	object[181]	giv[181]	coref	26-10[211_181]
23-12	3853-3858	cells	object[181]	giv[181]	_	_
23-13	3859-3862	are	_	_	_	_
23-14	3863-3871	selected	_	_	_	_
23-15	3872-3880	directly	_	_	_	_
23-16	3881-3882	.	_	_	_	_

#Text=For example , Lipovšek et al. reported in vitro selection of catalytically active enzymes ( horseradish peroxidase ) from large libraries of variants displayed on the surface of the yeast S. cerevisiae and separated by FACS .
24-1	3883-3886	For	_	_	_	_
24-2	3887-3894	example	_	_	_	_
24-3	3895-3896	,	_	_	_	_
24-4	3897-3905	Lipovšek	person	new	_	_
24-5	3906-3908	et	_	_	_	_
24-6	3909-3912	al.	_	_	_	_
24-7	3913-3921	reported	_	_	_	_
24-8	3922-3924	in	_	_	_	_
24-9	3925-3930	vitro	abstract[183]	giv[183]	coref	28-46[241_183]
24-10	3931-3940	selection	abstract[183]	giv[183]	_	_
24-11	3941-3943	of	abstract[183]	giv[183]	_	_
24-12	3944-3957	catalytically	abstract[183]|substance[184]	giv[183]|giv[184]	_	_
24-13	3958-3964	active	abstract[183]|substance[184]	giv[183]|giv[184]	_	_
24-14	3965-3972	enzymes	abstract[183]|substance[184]	giv[183]|giv[184]	_	_
24-15	3973-3974	(	_	_	_	_
24-16	3975-3986	horseradish	object|object[186]	new|new[186]	_	_
24-17	3987-3997	peroxidase	object[186]	new[186]	_	_
24-18	3998-3999	)	_	_	_	_
24-19	4000-4004	from	_	_	_	_
24-20	4005-4010	large	place[187]	new[187]	_	_
24-21	4011-4020	libraries	place[187]	new[187]	_	_
24-22	4021-4023	of	place[187]	new[187]	_	_
24-23	4024-4032	variants	place[187]|object	new[187]|giv	_	_
24-24	4033-4042	displayed	_	_	_	_
24-25	4043-4045	on	_	_	_	_
24-26	4046-4049	the	place[189]	new[189]	_	_
24-27	4050-4057	surface	place[189]	new[189]	_	_
24-28	4058-4060	of	place[189]	new[189]	_	_
24-29	4061-4064	the	place[189]|animal[190]	new[189]|new[190]	_	_
24-30	4065-4070	yeast	place[189]|animal[190]	new[189]|new[190]	_	_
24-31	4071-4073	S.	_	_	_	_
24-32	4074-4084	cerevisiae	_	_	_	_
24-33	4085-4088	and	_	_	_	_
24-34	4089-4098	separated	_	_	_	_
24-35	4099-4101	by	_	_	_	_
24-36	4102-4106	FACS	object	giv	coref	25-24
24-37	4107-4108	.	_	_	_	_

#Text=To improve substrate specificity of glycosyltransferases by directed evolution , Aharoni et al. screened a library of over a million sialyltransferases mutants using FACS and found a variant with up to 400-fold higher catalytic efficiency for transfer to a variety of fluorescently labeled acceptor sugars .
25-1	4109-4111	To	_	_	_	_
25-2	4112-4119	improve	_	_	_	_
25-3	4120-4129	substrate	person|abstract[193]	new|new[193]	_	_
25-4	4130-4141	specificity	abstract[193]	new[193]	_	_
25-5	4142-4144	of	abstract[193]	new[193]	_	_
25-6	4145-4165	glycosyltransferases	abstract[193]|substance[194]	new[193]|new[194]	_	_
25-7	4166-4168	by	abstract[193]|substance[194]	new[193]|new[194]	_	_
25-8	4169-4177	directed	abstract[193]|substance[194]|abstract[195]	new[193]|new[194]|giv[195]	_	_
25-9	4178-4187	evolution	abstract[193]|substance[194]|abstract[195]	new[193]|new[194]|giv[195]	_	_
25-10	4188-4189	,	abstract[193]|substance[194]	new[193]|new[194]	_	_
25-11	4190-4197	Aharoni	abstract[193]|substance[194]|person	new[193]|new[194]|new	_	_
25-12	4198-4200	et	abstract[193]|substance[194]	new[193]|new[194]	_	_
25-13	4201-4204	al.	abstract[193]|substance[194]	new[193]|new[194]	_	_
25-14	4205-4213	screened	_	_	_	_
25-15	4214-4215	a	organization[197]	new[197]	_	_
25-16	4216-4223	library	organization[197]	new[197]	_	_
25-17	4224-4226	of	organization[197]	new[197]	_	_
25-18	4227-4231	over	organization[197]|quantity[199]	new[197]|giv[199]	_	_
25-19	4232-4233	a	organization[197]|quantity[199]	new[197]|giv[199]	_	_
25-20	4234-4241	million	organization[197]|quantity[199]	new[197]|giv[199]	_	_
25-21	4242-4260	sialyltransferases	organization[197]|object|quantity[199]	new[197]|new|giv[199]	_	_
25-22	4261-4268	mutants	organization[197]|quantity[199]	new[197]|giv[199]	_	_
25-23	4269-4274	using	_	_	_	_
25-24	4275-4279	FACS	object	giv	coref	26-37
25-25	4280-4283	and	_	_	_	_
25-26	4284-4289	found	_	_	_	_
25-27	4290-4291	a	object[201]	giv[201]	_	_
25-28	4292-4299	variant	object[201]	giv[201]	_	_
25-29	4300-4304	with	object[201]	giv[201]	_	_
25-30	4305-4307	up	object[201]	giv[201]	_	_
25-31	4308-4310	to	object[201]	giv[201]	_	_
25-32	4311-4319	400-fold	object[201]|abstract[202]	giv[201]|giv[202]	_	_
25-33	4320-4326	higher	object[201]|abstract[202]	giv[201]|giv[202]	_	_
25-34	4327-4336	catalytic	object[201]|abstract[202]	giv[201]|giv[202]	_	_
25-35	4337-4347	efficiency	object[201]|abstract[202]	giv[201]|giv[202]	_	_
25-36	4348-4351	for	object[201]|abstract[202]	giv[201]|giv[202]	_	_
25-37	4352-4360	transfer	object[201]|abstract[202]|abstract[203]	giv[201]|giv[202]|new[203]	coref	26-22[0_203]
25-38	4361-4363	to	object[201]|abstract[202]|abstract[203]	giv[201]|giv[202]|new[203]	_	_
25-39	4364-4365	a	object[201]|abstract[202]|abstract[203]|abstract[204]	giv[201]|giv[202]|new[203]|new[204]	_	_
25-40	4366-4373	variety	object[201]|abstract[202]|abstract[203]|abstract[204]	giv[201]|giv[202]|new[203]|new[204]	_	_
25-41	4374-4376	of	object[201]|abstract[202]|abstract[203]|abstract[204]	giv[201]|giv[202]|new[203]|new[204]	_	_
25-42	4377-4390	fluorescently	object[201]|abstract[202]|abstract[203]|abstract[204]|substance[206]	giv[201]|giv[202]|new[203]|new[204]|new[206]	_	_
25-43	4391-4398	labeled	object[201]|abstract[202]|abstract[203]|abstract[204]|substance[206]	giv[201]|giv[202]|new[203]|new[204]|new[206]	_	_
25-44	4399-4407	acceptor	object[201]|abstract[202]|abstract[203]|abstract[204]|person|substance[206]	giv[201]|giv[202]|new[203]|new[204]|new|new[206]	_	_
25-45	4408-4414	sugars	object[201]|abstract[202]|abstract[203]|abstract[204]|substance[206]	giv[201]|giv[202]|new[203]|new[204]|new[206]	_	_
25-46	4415-4416	.	_	_	_	_

#Text=In their study , the formation of sialosides in intact E. coli cells was detected by selectively trapping the fluorescently labeled transfer products within the cell and the resulting cell population was analyzed and sorted using FACS .
26-1	4417-4419	In	_	_	_	_
26-2	4420-4425	their	abstract|abstract[208]	giv|new[208]	_	_
26-3	4426-4431	study	abstract[208]	new[208]	_	_
26-4	4432-4433	,	_	_	_	_
26-5	4434-4437	the	abstract[209]	new[209]	_	_
26-6	4438-4447	formation	abstract[209]	new[209]	_	_
26-7	4448-4450	of	abstract[209]	new[209]	_	_
26-8	4451-4461	sialosides	abstract[209]|substance	new[209]|new	_	_
26-9	4462-4464	in	abstract[209]	new[209]	_	_
26-10	4465-4471	intact	abstract[209]|object[211]	new[209]|giv[211]	coref	28-31[236_211]
26-11	4472-4474	E.	abstract[209]|object[211]	new[209]|giv[211]	_	_
26-12	4475-4479	coli	abstract[209]|object[211]	new[209]|giv[211]	_	_
26-13	4480-4485	cells	abstract[209]|object[211]	new[209]|giv[211]	_	_
26-14	4486-4489	was	_	_	_	_
26-15	4490-4498	detected	_	_	_	_
26-16	4499-4501	by	_	_	_	_
26-17	4502-4513	selectively	_	_	_	_
26-18	4514-4522	trapping	_	_	_	_
26-19	4523-4526	the	object[213]	new[213]	_	_
26-20	4527-4540	fluorescently	object[213]	new[213]	_	_
26-21	4541-4548	labeled	object[213]	new[213]	_	_
26-22	4549-4557	transfer	abstract|object[213]	giv|new[213]	_	_
26-23	4558-4566	products	object[213]	new[213]	_	_
26-24	4567-4573	within	object[213]	new[213]	_	_
26-25	4574-4577	the	object[213]|object[214]	new[213]|giv[214]	coref	26-30[0_214]
26-26	4578-4582	cell	object[213]|object[214]	new[213]|giv[214]	_	_
26-27	4583-4586	and	_	_	_	_
26-28	4587-4590	the	abstract[216]	giv[216]	_	_
26-29	4591-4600	resulting	abstract[216]	giv[216]	_	_
26-30	4601-4605	cell	object|abstract[216]	giv|giv[216]	coref	27-21[222_0]
26-31	4606-4616	population	abstract[216]	giv[216]	_	_
26-32	4617-4620	was	_	_	_	_
26-33	4621-4629	analyzed	_	_	_	_
26-34	4630-4633	and	_	_	_	_
26-35	4634-4640	sorted	_	_	_	_
26-36	4641-4646	using	_	_	_	_
26-37	4647-4651	FACS	object	giv	coref	27-13
26-38	4652-4653	.	_	_	_	_

#Text=However , many desirable properties are not amenable to direct interrogation via FACS because the phenotype is not inherent in a single cell , for example , when improving a protein excreted into growth medium .
27-1	4654-4661	However	_	_	_	_
27-2	4662-4663	,	_	_	_	_
27-3	4664-4668	many	abstract[218]	giv[218]	coref	28-1[226_218]
27-4	4669-4678	desirable	abstract[218]	giv[218]	_	_
27-5	4679-4689	properties	abstract[218]	giv[218]	_	_
27-6	4690-4693	are	_	_	_	_
27-7	4694-4697	not	_	_	_	_
27-8	4698-4706	amenable	_	_	_	_
27-9	4707-4709	to	_	_	_	_
27-10	4710-4716	direct	_	_	_	_
27-11	4717-4730	interrogation	abstract[219]	new[219]	_	_
27-12	4731-4734	via	abstract[219]	new[219]	_	_
27-13	4735-4739	FACS	abstract[219]|abstract	new[219]|giv	_	_
27-14	4740-4747	because	_	_	_	_
27-15	4748-4751	the	abstract[221]	new[221]	coref	28-43[240_221]
27-16	4752-4761	phenotype	abstract[221]	new[221]	_	_
27-17	4762-4764	is	_	_	_	_
27-18	4765-4768	not	_	_	_	_
27-19	4769-4777	inherent	_	_	_	_
27-20	4778-4780	in	_	_	_	_
27-21	4781-4782	a	object[222]	giv[222]	_	_
27-22	4783-4789	single	object[222]	giv[222]	_	_
27-23	4790-4794	cell	object[222]	giv[222]	_	_
27-24	4795-4796	,	_	_	_	_
27-25	4797-4800	for	_	_	_	_
27-26	4801-4808	example	_	_	_	_
27-27	4809-4810	,	_	_	_	_
27-28	4811-4815	when	_	_	_	_
27-29	4816-4825	improving	_	_	_	_
27-30	4826-4827	a	substance[223]	giv[223]	_	_
27-31	4828-4835	protein	substance[223]	giv[223]	_	_
27-32	4836-4844	excreted	_	_	_	_
27-33	4845-4849	into	_	_	_	_
27-34	4850-4856	growth	abstract|substance[225]	new|new[225]	_	_
27-35	4857-4863	medium	substance[225]	new[225]	_	_
27-36	4864-4865	.	_	_	_	_

#Text=Properties such as extracellular analyte consumption , product secretion and cell-cell interactions are not readily detectable with flow cytometry . Screening for ‘ non-cellular ’ phenotypes necessitates the compartmentalization of single cells or an alternative expression system to maintain the linkage between the phenotype that the selection acts on and the genotype in which the evolutionary information is encoded .
28-1	4866-4876	Properties	abstract[226]	giv[226]	_	_
28-2	4877-4881	such	abstract[226]	giv[226]	_	_
28-3	4882-4884	as	abstract[226]	giv[226]	_	_
28-4	4885-4898	extracellular	abstract[226]|abstract[228]	giv[226]|new[228]	_	_
28-5	4899-4906	analyte	abstract[226]|abstract|abstract[228]	giv[226]|new|new[228]	_	_
28-6	4907-4918	consumption	abstract[226]|abstract[228]	giv[226]|new[228]	_	_
28-7	4919-4920	,	abstract[226]	giv[226]	_	_
28-8	4921-4928	product	abstract[226]|abstract|substance[230]	giv[226]|new|new[230]	_	_
28-9	4929-4938	secretion	abstract[226]|substance[230]	giv[226]|new[230]	_	_
28-10	4939-4942	and	abstract[226]	giv[226]	_	_
28-11	4943-4952	cell-cell	abstract[226]|abstract[231]	giv[226]|new[231]	_	_
28-12	4953-4965	interactions	abstract[226]|abstract[231]	giv[226]|new[231]	_	_
28-13	4966-4969	are	_	_	_	_
28-14	4970-4973	not	_	_	_	_
28-15	4974-4981	readily	_	_	_	_
28-16	4982-4992	detectable	_	_	_	_
28-17	4993-4997	with	_	_	_	_
28-18	4998-5002	flow	abstract|abstract[233]	new|new[233]	_	_
28-19	5003-5012	cytometry	abstract[233]	new[233]	_	_
28-20	5013-5014	.	_	_	_	_
28-21	5015-5024	Screening	_	_	_	_
28-22	5025-5028	for	_	_	_	_
28-23	5029-5030	‘	abstract[234]	new[234]	_	_
28-24	5031-5043	non-cellular	abstract[234]	new[234]	_	_
28-25	5044-5045	’	abstract[234]	new[234]	_	_
28-26	5046-5056	phenotypes	abstract[234]	new[234]	_	_
28-27	5057-5069	necessitates	_	_	_	_
28-28	5070-5073	the	abstract[235]	new[235]	_	_
28-29	5074-5094	compartmentalization	abstract[235]	new[235]	_	_
28-30	5095-5097	of	abstract[235]	new[235]	_	_
28-31	5098-5104	single	abstract[235]|object[236]	new[235]|giv[236]	_	_
28-32	5105-5110	cells	abstract[235]|object[236]	new[235]|giv[236]	_	_
28-33	5111-5113	or	abstract[235]|object[236]	new[235]|giv[236]	_	_
28-34	5114-5116	an	abstract[235]|object[236]|abstract[238]	new[235]|giv[236]|new[238]	_	_
28-35	5117-5128	alternative	abstract[235]|object[236]|abstract[238]	new[235]|giv[236]|new[238]	_	_
28-36	5129-5139	expression	abstract[235]|object[236]|abstract|abstract[238]	new[235]|giv[236]|new|new[238]	_	_
28-37	5140-5146	system	abstract[235]|object[236]|abstract[238]	new[235]|giv[236]|new[238]	_	_
28-38	5147-5149	to	_	_	_	_
28-39	5150-5158	maintain	_	_	_	_
28-40	5159-5162	the	abstract[239]	new[239]	_	_
28-41	5163-5170	linkage	abstract[239]	new[239]	_	_
28-42	5171-5178	between	abstract[239]	new[239]	_	_
28-43	5179-5182	the	abstract[239]|abstract[240]	new[239]|giv[240]	_	_
28-44	5183-5192	phenotype	abstract[239]|abstract[240]	new[239]|giv[240]	_	_
28-45	5193-5197	that	_	_	_	_
28-46	5198-5201	the	abstract[241]	giv[241]	_	_
28-47	5202-5211	selection	abstract[241]	giv[241]	_	_
28-48	5212-5216	acts	_	_	_	_
28-49	5217-5219	on	_	_	_	_
28-50	5220-5223	and	_	_	_	_
28-51	5224-5227	the	abstract[242]	new[242]	_	_
28-52	5228-5236	genotype	abstract[242]	new[242]	_	_
28-53	5237-5239	in	_	_	_	_
28-54	5240-5245	which	_	_	_	_
28-55	5246-5249	the	abstract[243]	giv[243]	_	_
28-56	5250-5262	evolutionary	abstract[243]	giv[243]	_	_
28-57	5263-5274	information	abstract[243]	giv[243]	_	_
28-58	5275-5277	is	_	_	_	_
28-59	5278-5285	encoded	_	_	_	_
28-60	5286-5287	.	_	_	_	_

#Text=Compartmentalization of assays in arrays of wells makes microtiter plates by far the most widely used screening platform .
29-1	5288-5308	Compartmentalization	abstract[244]	new[244]	_	_
29-2	5309-5311	of	abstract[244]	new[244]	_	_
29-3	5312-5318	assays	abstract[244]|place	new[244]|new	_	_
29-4	5319-5321	in	abstract[244]	new[244]	_	_
29-5	5322-5328	arrays	abstract[244]|place[246]	new[244]|new[246]	_	_
29-6	5329-5331	of	abstract[244]|place[246]	new[244]|new[246]	_	_
29-7	5332-5337	wells	abstract[244]|place[246]|person	new[244]|new[246]|new	_	_
29-8	5338-5343	makes	_	_	_	_
29-9	5344-5354	microtiter	object[248]	new[248]	coref	31-9[260_248]
29-10	5355-5361	plates	object[248]	new[248]	_	_
29-11	5362-5364	by	object[248]	new[248]	_	_
29-12	5365-5368	far	object[248]|abstract[250]	new[248]|new[250]	_	_
29-13	5369-5372	the	object[248]|abstract[250]	new[248]|new[250]	_	_
29-14	5373-5377	most	object[248]|abstract[250]	new[248]|new[250]	_	_
29-15	5378-5384	widely	object[248]|abstract[250]	new[248]|new[250]	_	_
29-16	5385-5389	used	object[248]|abstract[250]	new[248]|new[250]	_	_
29-17	5390-5399	screening	object[248]|abstract|abstract[250]	new[248]|giv|new[250]	_	_
29-18	5400-5408	platform	object[248]|abstract[250]	new[248]|new[250]	_	_
29-19	5409-5410	.	_	_	_	_

#Text=However , the microplate-based method becomes problematic when the assay volume is less than 1 µL due to evaporation and capillary forces .
30-1	5411-5418	However	_	_	_	_
30-2	5419-5420	,	_	_	_	_
30-3	5421-5424	the	abstract[251]	new[251]	_	_
30-4	5425-5441	microplate-based	abstract[251]	new[251]	_	_
30-5	5442-5448	method	abstract[251]	new[251]	_	_
30-6	5449-5456	becomes	_	_	_	_
30-7	5457-5468	problematic	_	_	_	_
30-8	5469-5473	when	_	_	_	_
30-9	5474-5477	the	quantity[253]	new[253]	coref	30-13[254_253]
30-10	5478-5483	assay	object|quantity[253]	new|new[253]	coref	31-25[265_0]
30-11	5484-5490	volume	quantity[253]	new[253]	_	_
30-12	5491-5493	is	_	_	_	_
30-13	5494-5498	less	quantity[254]	giv[254]	_	_
30-14	5499-5503	than	quantity[254]	giv[254]	_	_
30-15	5504-5505	1	quantity[254]	giv[254]	_	_
30-16	5506-5508	µL	quantity[254]	giv[254]	_	_
30-17	5509-5512	due	quantity[254]	giv[254]	_	_
30-18	5513-5515	to	_	_	_	_
30-19	5516-5527	evaporation	abstract	new	_	_
30-20	5528-5531	and	_	_	_	_
30-21	5532-5541	capillary	abstract|abstract[257]	new|new[257]	_	_
30-22	5542-5548	forces	abstract[257]	new[257]	_	_
30-23	5549-5550	.	_	_	_	_

#Text=Even with robotic automation for liquid handling using 1536-well plates and assuming a processing rate of 1 plate per minute , the throughput of a well based assay is approximately 25 samples/sec for a prompt optical measurement .
31-1	5551-5555	Even	event[258]	new[258]	_	_
31-2	5556-5560	with	event[258]	new[258]	_	_
31-3	5561-5568	robotic	event[258]	new[258]	_	_
31-4	5569-5579	automation	event[258]	new[258]	_	_
31-5	5580-5583	for	event[258]	new[258]	_	_
31-6	5584-5590	liquid	event[258]|substance	new[258]|new	_	_
31-7	5591-5599	handling	_	_	_	_
31-8	5600-5605	using	_	_	_	_
31-9	5606-5615	1536-well	object[260]	giv[260]	_	_
31-10	5616-5622	plates	object[260]	giv[260]	_	_
31-11	5623-5626	and	_	_	_	_
31-12	5627-5635	assuming	_	_	_	_
31-13	5636-5637	a	abstract[261]	new[261]	_	_
31-14	5638-5648	processing	abstract[261]	new[261]	_	_
31-15	5649-5653	rate	abstract[261]	new[261]	_	_
31-16	5654-5656	of	abstract[261]	new[261]	_	_
31-17	5657-5658	1	abstract[261]|time[262]	new[261]|new[262]	_	_
31-18	5659-5664	plate	abstract[261]|time[262]	new[261]|new[262]	_	_
31-19	5665-5668	per	abstract[261]|time[262]	new[261]|new[262]	_	_
31-20	5669-5675	minute	abstract[261]|time[262]|time	new[261]|new[262]|new	_	_
31-21	5676-5677	,	_	_	_	_
31-22	5678-5681	the	quantity[264]	new[264]	coref	31-30[266_264]
31-23	5682-5692	throughput	quantity[264]	new[264]	_	_
31-24	5693-5695	of	quantity[264]	new[264]	_	_
31-25	5696-5697	a	quantity[264]|object[265]	new[264]|giv[265]	_	_
31-26	5698-5702	well	quantity[264]|object[265]	new[264]|giv[265]	_	_
31-27	5703-5708	based	quantity[264]|object[265]	new[264]|giv[265]	_	_
31-28	5709-5714	assay	quantity[264]|object[265]	new[264]|giv[265]	_	_
31-29	5715-5717	is	_	_	_	_
31-30	5718-5731	approximately	quantity[266]	giv[266]	_	_
31-31	5732-5734	25	quantity[266]	giv[266]	_	_
31-32	5735-5746	samples/sec	quantity[266]	giv[266]	_	_
31-33	5747-5750	for	quantity[266]	giv[266]	_	_
31-34	5751-5752	a	quantity[266]|event[267]	giv[266]|new[267]	_	_
31-35	5753-5759	prompt	quantity[266]|event[267]	giv[266]|new[267]	_	_
31-36	5760-5767	optical	quantity[266]|event[267]	giv[266]|new[267]	_	_
31-37	5768-5779	measurement	quantity[266]|event[267]	giv[266]|new[267]	_	_
31-38	5780-5781	.	_	_	_	_
